AI 081
Alternative Names: AI-081Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator AcroImmune
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Dec 2024 US FDA approves IND application for AI 081 in Solid tumours
- 02 Dec 2024 OncoC4 plans to initiate the phase I/II BIPAVE-001 trial for Solid tumours (Late-stage disease, Metastatic disease) in Q1 2025 (NCT06635785)
- 25 Sep 2024 Preclinical trials in Cancer in Australia (PO), prior to September 2024